Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Infusion vs Intermittent Bolus Adductor Canal Block for TKA
NCT05518513Recruiting
- Sponsor
- National Cheng Kung University Hospital
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bupivacaine in postoperative pain (3 arms), sponsored by National Cheng Kung University Hospital. Primary endpoint: Accumulated morphine consumption at 48 hours. Started Nov 2022; status: recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05518513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518513.